Nesa World
Nesa World is a privately held Spanish medical technology company that develops and distributes NESA XSIGNAL®, a Class IIa non-invasive autonomic neuromodulation device sold to independent clinics, hospitals, and research institutions across 47+ countries for chronic pain, sleep, fatigue, and urological indications.
- Company typePrivate
- Founded-
- HeadquartersDonostia-san Sebastián, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nesa World does
Nesa World (legally NGS Health and Mind S.L.) is a privately held Spanish medical technology company headquartered in San Sebastián (Donostia), Spain, that develops and distributes NESA XSIGNAL®, a Class IIa medical device for non-invasive autonomic neuromodulation. The device applies subsensory microcurrents (below 1 mA) through 24 surface electrodes placed on the wrists and ankles, delivering up to 19,000 bioelectrical impulses per minute at frequencies between 1 and 14 Hz. Its mechanism acts through three complementary pathways: classical afferent neurotransmission via peripheral nerves to the brainstem, bioelectrical communication through the piezoelectric fascial network, and neuroimmune modulation via the vagal pathway, with the goal of restoring sympathetic-parasympathetic balance in patients with chronic pain, sleep disturbances, fatigue, overactive bladder, stress, and related conditions.
The company sells the device through three tiers (Esencial, Profesional, Premium) to independent clinics, hospitals, and research institutions across more than 47 countries, with over 1,000 clinics and 50+ hospitals in its installed base and 4M+ cumulative patient sessions performed. Revenue is generated primarily through one-time hardware sales (with flexible acquisition options including outright purchase, payment plans, and rental for select home use), supplemented by recurring consumables (personal patient kits assigned per patient for hygiene and traceability), training and education services via the NESA Academic campus, and scientific dossier and research support services. Distribution combines a direct authorized clinic network, regional distributors, and academic/hospital research partnerships, supported by a public clinic locator and a multi-language marketing presence targeting healthcare professionals across rehabilitation, urogynecology, sports medicine, mental health, neurology, dentistry, internal medicine, and aesthetic medicine.
Nesa World's competitive positioning rests on more than three decades of technology evolution from a 192-electrode Japanese prototype, a portfolio of 16+ peer-reviewed clinical studies in indexed journals, a dedicated Electrophysiology Laboratory at ULPGC, and 15+ institutional research collaborations. The company is privately held with no disclosed external funding rounds, and operates with a headcount of 11–50 employees.
Nesa World firmographics
Firmographics- Name
- Nesa World
- Legal name
- NGS Health and Mind S.L
- Website
- https://nesa.world
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nesa World is a privately held Spanish medical technology company that develops and distributes NESA XSIGNAL®, a Class IIa non-invasive autonomic neuromodulation device sold to independent clinics, hospitals, and research institutions across 47+ countries for chronic pain, sleep, fatigue, and urological indications.
- Ownership category
- akta.pro rank
Where Nesa World is headquartered
LocationHeadquarters
- HQ city
- Donostia-san Sebastián
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Nesa World business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales – NESA XSIGNAL®: Nesa World sells NESA XSIGNAL® medical devices (Class IIa) to healthcare professionals and clinics through a tiered offering model (Esencial, Profesional, Premium). The device is offered with flexible acquisition options including outright purchase, payment plans, and device rental for home treatment in select cases. Many clinics amortize the investment within the first months by bundling the device into session packages. Each tier includes varying levels of onboarding, training, clinical materials, and support. The revenue is predominantly a one-time capital expense for the device, supplemented by ongoing consumables (personal patient kits) and potentially premium support contracts.
- Session Packages and Treatment Programs: NESA Clinics (partner clinics) offer NESA neuromodulation sessions to patients, typically structured as session packages or blocks rather than single-session bookings. Each clinic sets its own pricing. Treatment programs include a comprehensive initial assessment, a personal patient kit, a series of sessions with a personalized plan, measurement tools (validated questionnaires, ECG/HRV in many cases), and regular reassessments. Revenue flows to the clinic, not directly to Nesa World, but this drives clinic adoption of the device.
- Training and Education – NESA Academic: Nesa World provides online and in-person training via the NESA Academic campus, integrated into device tier packages (Esencial includes basic online training; Profesional adds advanced online or in-person training; Premium includes on-site accompaniment and mentoring). Training is a value driver for adoption and may represent an additional service revenue stream.
- Scientific Dossier and Research Support Services: Nesa World produces and distributes a biannual scientific dossier compiling completed research, ongoing studies, and pending projects (available to professionals and collaborators). They also provide technical, academic, and operational support to hospitals and universities for integrating non-invasive neuromodulation into their own research lines, including doctoral thesis support. This reinforces brand credibility and drives institutional adoption.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Esencial tier: Core device package with basic accessories and online training |
| One time/ perpetual license | Multi-year contract | Profesional tier (most popular): Expanded kit, advanced training, and enhanced support |
| One time/ perpetual license | Multi-year contract | Premium tier: On-site accompaniment, advanced mentoring, and priority continuous support |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels10 records
Nesa World product offering
Product offeringCore offering
Nesa World (legally NGS Health and Mind S.L.) develops and commercializes NESA XSIGNAL®, a Class IIa non-invasive neuromodulation medical device that delivers subsensory microcurrents through 24 surface electrodes placed at distal low-impedance points to modulate the autonomic nervous system. The device is offered to healthcare professionals and clinics in three tiers (Esencial, Profesional, Premium), complemented by per-patient Personal Patient Kit consumables and the NESA Academic training campus.
Product overview
Nesa World offers non-invasive neuromodulation technology through its flagship product NESA XSIGNAL®, a Class IIa medical device that applies microcurrents to modulate the autonomic nervous system. The company provides this through three service tiers (Esencial, Profesional, Premium) which differ in level of support, training, and materials rather than the device itself. NESA XSIGNAL® is available in clinics across 47+ countries and serves multiple clinical specialties including rehabilitation, intimate health, sports medicine, mental health, neurology, dentistry, internal medicine, and aesthetic medicine.
Differentiator
Problem solved
Functional benefit
Brands
- NESA XSIGNAL®: Class IIa medical device for non-invasive neuromodulation of the autonomic nervous system using microcurrents applied through electrodes on wrists and ankles.
- Nesa Clinics
- Nesa Academic
Quantifiable outcome
- Sleep quality improvement: up to 49.0% improvement; REM sleep strength +20.1%; total hours of sleep +23.7%; nocturnal awakenings -64.4%; sleep interruptions -69.5%; daytime sleepiness -57.9%; family sleep quality +24.0%
- +7 more outcomes
Companies that use Nesa World
Customer profileNamed customers10 records
Segments10 records
Ideal customer profiles2 records
Nesa World technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nesa World partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core.
- Universidad de Las Palmas de Gran Canaria (ULPGC)coreNESA World established its Electrophysiology Laboratory at ULPGC in 2019. The lab is equipped with specialized tools for autonomic nervous system analysis, actigraphy, ECG, EGG, and biomarkers. It leads proprietary research projects and collaborates with external research groups. The lab produces a biannual scientific dossier of completed research, ongoing studies, and pending projects, distributed to professionals and collaborators. This is a flagship research partnership providing the scientific foundation for NESA technology.
- Universidad Europea de Madrid (UE)coreFormal research agreement for NESA neuromodulation studies. The university's I+D Laboratory (led by Dr. Carlos Romero) and faculty members including Dr. Monica de la Cueva and Beatriz Martinez (pelvic floor physiotherapist and teacher) participate in collaborative research on NESA applications across clinical areas.
- Universidad Rey Juan Carlos (URJC)coreResearch collaboration including work on long COVID dysautonomia. Dr. Cesar Fernandez de las Peñas and Dr. Ana Isabel de la Llave are key collaborators. URJC participates in the Long COVID unit research with NESA neuromodulation. Dr. Raquel Medina also collaborates directly with ULPGC.
- Universidad de Castilla-La Mancha (UCLM)coreFormal research agreement with UCLM. Dr. Raquel Medina serves as laboratory director. Rectors and deans have participated in agreement ceremonies. The collaboration supports doctoral thesis development and independent research on autonomic neuromodulation.
- Universidad Alfonso X El Sabio (UAX)coreNESA Electrophysiology Laboratory established at UAX. Collaboration includes Rector Isabel Fernandez, Health Sciences Director, faculty members Pablo Aparicio and Dr. Lopez Roman (Director of the Virtual Hospital). Supports academic research and training in NESA neuromodulation applications.
- Universidad de Alcala (UAH)coreNESA Electrophysiology Laboratory at UAH. Dr. Tomas Gallego (Dean of Physiotherapy) and Dr. Daniel Pecos (Vice-Dean) participate in collaborative research and academic activities related to autonomic neuromodulation.
- FC Barcelona Innovation Hub (Barça Innovation Hub)coreResearch collaboration with FC Barcelona's innovation hub studying the 'neuroefficiency' of basketball players using NESA technology. A published clinical trial (García et al., 2022, Frontiers in Physiology) demonstrated improved physiological recovery in professional basketball players. The partnership provides high-profile sports medicine credibility and athlete-specific outcomes data.
- Clinica Sant JosepcoreClinical trial partnership studying improved recovery in anterior cruciate ligament (ACL) reconstruction with NESA neuromodulation. Key collaborators include Dr. Jordi Puigdelli (FC Barcelona Traumatologist), Dr. Albert Estiarte (Director), Dr. Griselda Sirvent (Head of Rehabilitation), and Oscar Muncunill (Physiotherapist). Produces clinical evidence for sports rehabilitation applications.
- Servicio Canario de la SaludcoreClinical trial partnership studying overactive bladder improvement with NESA technology. Conducted at Hospital Materno Infantil with Dr. Alicia Martin (Gynecologist, Head of Service), Dr. Guillermo Conde (Urologist, Head of Service), and institutional collaborators. Produces peer-reviewed urology/gynecology evidence published in Journal of Clinical Medicine.
- Hospital San Juan de Dios (San Sebastian)coreResearch partnership studying post-operative improvement of knee prostheses with NESA neuromodulation. Key collaborators include Jose Carlos del Castillo (Medical Director), Dr. Inmaculada Fierro (Rehabilitation Medical Director), Dr. Ramon Moreno (Traumatologist), and Yaiza Rodriguez (Physiotherapist). Provides evidence for post-surgical rehabilitation applications.
- Ciudad San Juan de Dios Las PalmascoreResearch partnership studying improvement in constipation and nocturnal spasticity with NESA neuromodulation. Clinical coordinator Iraya Padron leads the collaboration, producing evidence for neurological and gastroenterological applications including pediatric neurodevelopmental disorders.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Nesa World competitors and assessment
Company assessmentBroad incumbents
- Magstim: Magstim is an established manufacturer of transcranial magnetic stimulation (TMS) systems and neuronavigation tools used in psychiatry, neurology, and neuroscience research. While it competes in the broader non-invasive neuromodulation category, its modality (magnetic rather than microcurrent) and customer profile (psychiatry and research hospitals) differ from NESA's autonomic/via-distal-electrodes approach.
- BTL Industries: BTL Industries manufactures a broad portfolio of non-invasive medical and aesthetic devices, including EMS body-shaping systems (Emsculpt), focused shockwave therapy, and high-intensity electromagnetic/electrical stimulation platforms sold to clinics globally. It is a broad incumbent in non-invasive clinic-grade electrical stimulation, but its core portfolio is aesthetic/orthopedic rather than autonomic neuromodulation.
- Neurosoft: Neurosoft produces a range of neurophysiological and neurostimulation equipment (EEG, EMG, TMS, and therapeutic stimulation devices) sold to hospitals and research institutions. Comparable as a broader medical-device incumbent in the neurostimulation space, though its offering spans many modalities beyond NESA's autonomic microcurrent focus.
Emerging players
- MindMaze: MindMaze develops digital neurotherapeutics, brain-computer interfaces, and neurorehabilitation platforms combining software and sensors for stroke recovery and cognitive assessment. Comparable as an emerging player that combines neuromodulation/neurotechnology with clinical evidence-driven positioning for rehabilitation, though its delivery modality (digital/BCI) differs from NESA's hardware-electrode approach.
- Dreem (Beacon Biosignals): Dreem (and parent Beacon Biosignals) develops neurotechnology and sleep-monitoring/EEG-based devices targeting sleep improvement and autonomic/sleep research. Comparable as an emerging neurotechnology player addressing sleep and autonomic regulation - key outcomes in NESA's published evidence - via a different modality (wearable/EEG headband).
Others
- Saluda Medical: Saluda Medical develops implantable closed-loop spinal cord stimulation systems for chronic pain and other neurological conditions, with FDA-cleared devices. Included as an adjacent/ecosystem peer in the neuromodulation space addressing chronic pain - one of NESA's core indications - though its invasive, surgical-implant approach contrasts with NESA's non-invasive positioning.
- Cosman Medical / Boston Scientific Neuromodulation: Boston Scientific's Neuromodulation division (which absorbed Cosman Medical's RF pain technology) is a global incumbent in spinal cord stimulation, radiofrequency ablation, and deep brain stimulation for chronic pain and movement disorders. Included as an adjacent large-cap incumbent whose pain-neuromodulation portfolio frames the market context for NESA's non-invasive chronic pain offering.
Direct peers
- Cefaly: Cefaly manufactures a non-invasive external trigeminal nerve stimulation device (Class II medical device) primarily indicated for migraine prevention and acute treatment, marketed to neurologists and headache specialists. Like Nesa World, Cefaly sells a hardware device through clinicians with a CE-marked, app-enabled, microcurrent-based neuromodulation platform targeting an underserved therapeutic area.
- electroCore (gammaCore): electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine, cluster headache, and autonomic-related indications, sold through healthcare providers and reimbursed in select markets. It is a direct functional analog to NESA XSIGNAL® in that both deliver non-invasive autonomic neuromodulation via surface electrodes to treat overlapping conditions including headache, pain, and autonomic dysregulation.
- Soterix Medical: Soterix Medical develops non-invasive transcranial direct current stimulation (tDCS) and transcranial electrical stimulation devices used in research and clinical neurology/rehabilitation settings. Comparable to Nesa World in deploying Class II-equivalent, electrode-based electrical neuromodulation hardware to clinicians and researchers for therapeutic and rehabilitation applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Nesa World social profiles
Digital presenceNesa World compliance and trust
Trust signalCompliance4 records
Nesa World financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nesa World leadership team
Management profileNumber of profiles
Nesa World funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nesa World M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nesa World
What does Nesa World do?
Nesa World (legally NGS Health and Mind S.L.) develops and commercializes NESA XSIGNAL®, a Class IIa non-invasive neuromodulation medical device that delivers subsensory microcurrents through 24 surface electrodes placed at distal low-impedance points to modulate the autonomic nervous system. The device is offered to healthcare professionals and clinics in three tiers (Esencial, Profesional, Premium), complemented by per-patient Personal Patient Kit consumables and the NESA Academic training campus.
Is Nesa World a public or private company?
Nesa World is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nesa World founded?
Nesa World was founded in -1. It employs 11 to 50 people.
Where is Nesa World based?
Nesa World is headquartered in Donostia-san Sebastián, Spain, in the Europe region.
How does Nesa World make money?
Four revenue lines are on record. Medical Device Sales – NESA XSIGNAL® is the primary driver. The others are session Packages and Treatment Programs, training and Education – NESA Academic and scientific Dossier and Research Support Services.
Who are Nesa World's main competitors?
Broad incumbents on record are Magstim, BTL Industries and Neurosoft. Emerging players are MindMaze and Dreem (Beacon Biosignals). Others are Saluda Medical and Cosman Medical / Boston Scientific Neuromodulation. Direct peers are Cefaly, electroCore (gammaCore) and Soterix Medical.
Does Nesa World have an API?
No public API is recorded for Nesa World.